NASDAQ:RDNT - RadNet Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.50
  • Forecasted Upside: 18.92 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$18.92
▲ +0.57 (3.11%)
1 month | 3 months | 12 months
Get New RadNet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDNT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$22.50
▲ +18.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for RadNet in the last 3 months. The average price target is $22.50, with a high forecast of $23.00 and a low forecast of $22.00. The average price target represents a 18.92% upside from the last price of $18.92.
Buy
The current consensus among 2 polled investment analysts is to buy stock in RadNet. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2020Raymond JamesBoost Price TargetOutperform$18.50 ➝ $22.00Medium
i
5/26/2020SidotiBoost Price TargetBuy$17.00 ➝ $23.00High
i
Rating by Mitra Ramgopal at Sidoti
2/21/2020SidotiBoost Price TargetBuy$23.00 ➝ $28.00Medium
i
Rating by Mitra Ramgopal at Sidoti
12/2/2019SidotiBoost Price TargetBuy$20.00 ➝ $23.00High
i
3/15/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$16.00 ➝ $17.50High
i
3/14/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$15.00Low
i
3/14/2018FIXInitiated CoverageStrong-Buy$15.00High
i
3/8/2018Jefferies Financial GroupSet Price TargetBuy$14.00High
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
8/22/2017Jefferies Financial GroupUpgradeHold ➝ Buy$7.00 ➝ $12.00High
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/16/2017Jefferies Financial GroupSet Price TargetHold$7.00High
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
11/10/2016Jefferies Financial GroupReiterated RatingHold$7.00N/A
i
11/9/2016Craig HallumDowngradeBuy ➝ HoldN/A
i
Rating by B. Bonello at Craig Hallum
9/3/2016B. RileyReiterated RatingBuy$9.00N/A
i
8/29/2016B. RileyReiterated RatingBuy$9.00N/A
i
8/14/2016B. RileyReiterated RatingBuy$9.00N/A
i
8/9/2016B. RileyReiterated RatingBuy$9.00N/A
i
8/5/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
8/4/2016B. RileyReiterated RatingBuy$9.00N/A
i
7/11/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
6/2/2016Sterne Agee CRTInitiated CoverageNeutralN/A
i
5/17/2016B. RileyReiterated RatingBuy$9.00N/A
i
5/12/2016B. RileyReiterated RatingBuy$9.00N/A
i
5/6/2016B. RileyReiterated RatingBuy$9.00N/A
i
4/15/2016SidotiInitiated CoverageBuy$9.00N/A
i
3/20/2016B. RileyReiterated RatingBuy$9.00N/A
i
3/15/2016B. RileyReiterated RatingBuy$9.00N/A
i
3/15/2016Jefferies Financial GroupLower Price TargetHold$10.00 ➝ $8.00N/A
i
3/10/2016B. RileyReiterated RatingBuy$12.50N/A
i
(Data available from 3/6/2016 forward)
RadNet logo
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of hospitals and hospital-based radiology groups. As of December 31, 2019, it operated 335 centers in California, Delaware, Florida, Maryland, New Jersey, and New York. RadNet, Inc. has a collaboration with Hologic, Inc. to advance the use of artificial intelligence in breast health. The company was founded in 1985 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $18.92
$18.08
$18.92

50 Day Range

MA: $19.06
$17.73
$21.00

52 Week Range

Now: $18.92
$5.81
$21.88

Volume

209,150 shs

Average Volume

183,255 shs

Market Capitalization

$976.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of RadNet?

The following Wall Street sell-side analysts have issued research reports on RadNet in the last twelve months: Raymond James, Sidoti, and Zacks Investment Research.
View the latest analyst ratings for RDNT.

What is the current price target for RadNet?

2 Wall Street analysts have set twelve-month price targets for RadNet in the last year. Their average twelve-month price target is $22.50, suggesting a possible upside of 18.9%. Sidoti has the highest price target set, predicting RDNT will reach $23.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $22.00 for RadNet in the next year.
View the latest price targets for RDNT.

What is the current consensus analyst rating for RadNet?

RadNet currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RDNT will outperform the market and that investors should add to their positions of RadNet.
View the latest ratings for RDNT.

What other companies compete with RadNet?

How do I contact RadNet's investor relations team?

RadNet's physical mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company's listed phone number is (310) 478-7808 and its investor relations email address is [email protected] The official website for RadNet is www.radnet.com.